Literature DB >> 33860184

Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes.

Gabrielle Agin-Liebes1,2, Trevor F Haas3,4, Rafael Lancelotta5, Malin V Uthaug6, Johannes G Ramaekers6, Alan K Davis7,8.   

Abstract

Mescaline is a naturally occurring psychoactive alkaloid that has been used as a sacrament by Indigenous populations in spiritual ritual and healing ceremonies for millennia. Despite promising early preliminary research and favorable anecdotal reports, there is limited research investigating mescaline's psychotherapeutic potential. We administered an anonymous online questionnaire to adults (N = 452) reporting use of mescaline in naturalistic settings about mental health benefits attributed to mescaline. We assessed respondents' self-reported improvements in depression, anxiety, post-traumatic stress disorder (PTSD), and alcohol and drug use disorders (AUD and DUD). Of the respondents reporting histories of these clinical conditions, most (68-86%) reported subjective improvement following their most memorable mescaline experience. Respondents who reported an improvement in their psychiatric conditions reported significantly higher ratings of acute psychological factors including mystical-type, psychological insight, and ego dissolution effects compared to those who did not report improvements (Cohen's d range 0.7 - 1.5). Many respondents (35-50%) rated the mescaline experience as the single or top five most spiritually significant or meaningful experience(s) of their lives. Acute experiences of psychological insight during their mescaline experience were associated with increased odds of reporting improvement in depression, anxiety, AUD and DUD. Additional research is needed to corroborate these preliminary findings and to rigorously examine the efficacy of mescaline for psychiatric treatment in controlled, longitudinal clinical trials.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 33860184      PMCID: PMC8033766          DOI: 10.1021/acsptsci.1c00018

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  56 in total

1.  The phenomenon of quantum change.

Authors:  William R Miller
Journal:  J Clin Psychol       Date:  2004-05

Review 2.  Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology.

Authors:  Ido Hartogsohn
Journal:  J Psychopharmacol       Date:  2016-11-16       Impact factor: 4.153

3.  Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.

Authors:  Michael P Bogenschutz; Alyssa A Forcehimes; Jessica A Pommy; Claire E Wilcox; P C R Barbosa; Rick J Strassman
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

Review 4.  MDA, MDMA, and other "mescaline-like" substances in the US military's search for a truth drug (1940s to 1960s).

Authors:  Torsten Passie; Udo Benzenhöfer
Journal:  Drug Test Anal       Date:  2017-12-05       Impact factor: 3.345

5.  Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.

Authors:  Anna Rickli; Olivier D Moning; Marius C Hoener; Matthias E Liechti
Journal:  Eur Neuropsychopharmacol       Date:  2016-05-20       Impact factor: 4.600

Review 6.  The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013.

Authors:  Zachary Steel; Claire Marnane; Changiz Iranpour; Tien Chey; John W Jackson; Vikram Patel; Derrick Silove
Journal:  Int J Epidemiol       Date:  2014-03-19       Impact factor: 7.196

Review 7.  Epidemiology and treatment of depression in patients with chronic medical illness.

Authors:  Wayne J Katon
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

8.  Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.

Authors:  Leor Roseman; David J Nutt; Robin L Carhart-Harris
Journal:  Front Pharmacol       Date:  2018-01-17       Impact factor: 5.810

9.  Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.

Authors:  Fernanda Palhano-Fontes; Dayanna Barreto; Heloisa Onias; Katia C Andrade; Morgana M Novaes; Jessica A Pessoa; Sergio A Mota-Rolim; Flávia L Osório; Rafael Sanches; Rafael G Dos Santos; Luís Fernando Tófoli; Gabriela de Oliveira Silveira; Mauricio Yonamine; Jordi Riba; Francisco R Santos; Antonio A Silva-Junior; João C Alchieri; Nicole L Galvão-Coelho; Bruno Lobão-Soares; Jaime E C Hallak; Emerson Arcoverde; João P Maia-de-Oliveira; Dráulio B Araújo
Journal:  Psychol Med       Date:  2018-06-15       Impact factor: 7.723

10.  Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.

Authors:  Alan K Davis; Frederick S Barrett; Darrick G May; Mary P Cosimano; Nathan D Sepeda; Matthew W Johnson; Patrick H Finan; Roland R Griffiths
Journal:  JAMA Psychiatry       Date:  2021-05-01       Impact factor: 21.596

View more
  7 in total

1.  Finding medical value in mescaline.

Authors:  Eric Bender
Journal:  Nature       Date:  2022-09       Impact factor: 69.504

Review 2.  Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico.

Authors:  Snehal R Bhatt; Maya Armstrong; Tassy Parker; Marcello Maviglia; Rebecca Kass; Lawrence Leeman; Paul Romo; Douglas Ziedonis
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

3.  Associations between classic psychedelics and nicotine dependence in a nationally representative sample.

Authors:  Grant Jones; Joshua Lipson; Matthew K Nock
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

4.  Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study.

Authors:  Grant M Jones; Matthew K Nock
Journal:  Sci Rep       Date:  2022-02-16       Impact factor: 4.996

5.  Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.

Authors:  Victoria Amalie Nygart; Lis Marie Pommerencke; Eline Haijen; Hannes Kettner; Mendel Kaelen; Erik Lykke Mortensen; David John Nutt; Robin Lester Carhart-Harris; David Erritzoe
Journal:  J Psychopharmacol       Date:  2022-08       Impact factor: 4.562

Review 6.  Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.

Authors:  Elaine Meade; Sarah Hehir; Neil Rowan; Mary Garvey
Journal:  J Fungi (Basel)       Date:  2022-03-11

Review 7.  Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.

Authors:  Anne K Schlag; Jacob Aday; Iram Salam; Jo C Neill; David J Nutt
Journal:  J Psychopharmacol       Date:  2022-02-02       Impact factor: 4.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.